Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. NVDA
3. SPCX
4. MU
5. LCO
6. KR
7. APGE
8. MSTR
9. ABBV
10. DFTX

Go back to Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
(NYSE: BHVN) Delayed: 15.32 +1.75 (12.90%)
Previous Close $13.57    52 Week High $ 
Open $14.07    52 Week Low $ 
Day High $15.50    P/E N/A 
Day Low $14.07    EPS $ 
Volume 1,204,733